As a group of medical oncologists treating breast cancer, it is no longer possible to explain the rationale and justification for the CADTH funding decision to our patients, nor to those looking to us for expert guidance on optimal curative-intent therapies for HER2 positive breast cancer. The gene discussed is ERBB2; the disease is breast cancer.